Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - locally advanced or metastatic bladder cancer in combination with other cytostatic medicinal products. - locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. the preceding chemotherapy should have included an anthracycline unless clinically contraindicated. - locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. palliative treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer. - locally advanced or metastatic adenocarcinoma of the pancreas in patients who are in good general condition with adequate bone marrow reserves. patients with 5-fluorouracil refractory pancreatic cancer.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; sodium hydroxide; hydrochloric acid - locally advanced or metastatic bladder cancer in combination with other cytostatic medicinal products. - locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. the preceding chemotherapy should have included an anthracycline unless clinically contraindicated. - locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. palliative treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer. - locally advanced or metastatic adenocarcinoma of the pancreas in patients who are in good general condition with adequate bone marrow reserves. patients with 5-fluorouracil refractory pancreatic cancer.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; sodium hydroxide; hydrochloric acid - locally advanced or metastatic bladder cancer in combination with other cytostatic medicinal products. - locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. the preceding chemotherapy should have included an anthracycline unless clinically contraindicated. - locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. palliative treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer. - locally advanced or metastatic adenocarcinoma of the pancreas in patients who are in good general condition with adequate bone marrow reserves. patients with 5-fluorouracil refractory pancreatic cancer.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; mannitol - cancer chemotherapeutic drug - details of indications do not appear in the leaflet as exported from hospira australia

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid; peg-35 castor oil; ethanol absolute - paclitaxel is used in the treatment of a number of types of cancer including ovarian cancer, breast cancer, and advanced non-small cell lung cancer. it is also used in aids-related kaposi's sarcoma.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - sodium chloride, quantity: 2.6 mg/ml; methotrexate, quantity: 25 mg/ml - injection - excipient ingredients: benzyl alcohol; sodium hydroxide; water for injections; hydrochloric acid - methotrexate injection usp belongs to a group of medicines known as anti-metabolites. it is used in high doses to treat certain types of cancers, including breast cancer, non-hodgkin's lymphoma and leukemia. at lower doses, it may also be used to treat severe psoriasis and severe rheumatoid arthritis.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - desferrioxamine mesilate, quantity: 500 mg - injection, powder for - excipient ingredients: water for injections - a) acute iron intoxication. b) chronic iron overload due to transfusion-dependent anemias. c) diagnosis of aluminium overload (desferrioxamine infusion test). d) chronic aluminium overload in patients with esrf under maintenance dialysis. in cases of acute iron intoxication, desferrioxamine is an adjunct to, and not a substitute for, standard therapeutic measures whuich may include: i) induction of emesis. ii) gastric lavage. iii) maintenance of clear airways. iv) control of peripheral vascular failure. v) correction of acidosis.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium chloride; mannitol; water for injections - cancer chemotherapeutic drug - details of the indications do not appear on the leaflet as exported from hospira australia

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - mitoxantrone (mitozantrone) hydrochloride, quantity: 2.33 mg/ml (equivalent: mitoxantrone, qty 2 mg/ml) - injection - excipient ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride; sodium metabisulfite - mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mitoxantrone in combination with other approved drus(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (anll) in adults. this category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.